The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
David Baker, Gareth Pryce, Louisa K. James, Mónica Marta, Klaus Schmierer
Topics & Concepts
OcrelizumabMedicineAlemtuzumabMultiple sclerosisCladribineInternal medicineAdverse effectPlaceboOncologyImmunologyRituximabTransplantationLymphomaPathologyAlternative medicineMultiple Sclerosis Research StudiesMonoclonal and Polyclonal Antibodies Researchvaccines and immunoinformatics approaches